ATE403651T1 - 3-fluoro-piperidine als nmda/nr2b antagonisten - Google Patents

3-fluoro-piperidine als nmda/nr2b antagonisten

Info

Publication number: ATE403651T1
Authority: AT; Austria
Prior art keywords: nmda; piperidine; fluoro; nr2b antagonists; nr2b
Prior art date: 2003-06-04

Application number

AT04753896T

Other languages

English (en)

Inventor

Nigel Liverton

Christopher Claiborne

David Claremon

John Mccauley

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-04

Filing date

2004-05-28

Publication date

2008-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33511734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE403651(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-28 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE403651T1 publication Critical patent/ATE403651T1/de

Links

YUKQZLBLVRAJSW-UHFFFAOYSA-N 3-fluoropiperidine Chemical compound FC1CCCNC1 YUKQZLBLVRAJSW-UHFFFAOYSA-N 0.000 title 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
102000034527 Retinoid X Receptors Human genes 0.000 title 1
108010038912 Retinoid X Receptors Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Immunology (AREA)
Addiction (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)

AT04753896T 2003-06-04 2004-05-28 3-fluoro-piperidine als nmda/nr2b antagonisten ATE403651T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US47593803P	2003-06-04	2003-06-04

Publications (1)

Publication Number	Publication Date
ATE403651T1 true ATE403651T1 (de)	2008-08-15

Family

ID=33511734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04753896T ATE403651T1 (de)	2003-06-04	2004-05-28	3-fluoro-piperidine als nmda/nr2b antagonisten

Country Status (30)

Country	Link
EP (1)	EP1648882B1 (de)
JP (1)	JP3927228B2 (de)
KR (1)	KR20060017839A (de)
CN (1)	CN1798744A (de)
AR (1)	AR044579A1 (de)
AT (1)	ATE403651T1 (de)
AU (1)	AU2004245522B2 (de)
BR (1)	BRPI0410837A (de)
CA (1)	CA2527093C (de)
CL (1)	CL2004001365A1 (de)
CO (1)	CO5700762A2 (de)
DE (1)	DE602004015610D1 (de)
DK (1)	DK1648882T3 (de)
EC (1)	ECSP056192A (de)
ES (1)	ES2309540T3 (de)
HR (1)	HRP20080490T3 (de)
IS (1)	IS8117A (de)
MA (1)	MA27781A1 (de)
MX (1)	MXPA05013151A (de)
MY (1)	MY138547A (de)
NO (1)	NO20060020L (de)
PE (1)	PE20050245A1 (de)
PL (1)	PL1648882T3 (de)
PT (1)	PT1648882E (de)
RU (1)	RU2339630C2 (de)
SI (1)	SI1648882T1 (de)
TW (1)	TW200510378A (de)
UA (1)	UA81319C2 (de)
WO (1)	WO2004108705A1 (de)
ZA (1)	ZA200509000B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007128056A1 (en) *	2006-05-03	2007-11-15	Cnsbio Pty Ltd	Methods and composition for treatment of inflammatory pain
RU2489431C2 (ru) *	2007-04-23	2013-08-10	Янссен Фармацевтика Н.В.	Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
WO2009000038A1 (en) *	2007-06-28	2008-12-31	Cnsbio Pty Ltd	Combination methods and compositions for treatment of neuropathic pain
KR20120123089A (ko)	2010-02-16	2012-11-07	화이자 인코포레이티드	5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
AU2013251079B2 (en)	2012-04-20	2017-03-23	Ucb Pharma S.A.	Methods for treating Parkinson's disease
CN103936663B (zh) *	2013-01-23	2016-12-28	艾琪康医药科技（上海）有限公司	一种1-r1-3,3-二氟(或3-氟)-4-r2-4-氨甲基哌啶及其衍生物的制备方法
US9221796B2 (en)	2014-01-09	2015-12-29	Bristol-Myers Squibb Company	Selective NR2B antagonists
US9187506B2 (en)	2014-01-09	2015-11-17	Bristol-Myers Squibb Company	(R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US10030026B2 (en)	2014-06-04	2018-07-24	Rugen Holdings (Cayman) Limited	Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
MX2017002775A (es)	2014-09-15	2017-08-10	Rugen Holdings (Cayman) Ltd	Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
US20180271869A1 (en) *	2014-09-22	2018-09-27	Jie Liu	Treatment of anxiety disorders and autism spectrum disorders
CA2970958A1 (en)	2014-12-23	2016-06-30	Cerecor, Inc.	Compounds, compositions and methods
US10221182B2 (en)	2015-02-04	2019-03-05	Rugen Holdings (Cayman) Limited	3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
CA2987606C (en) *	2015-06-01	2024-02-20	Rugen Holdings (Cayman) Limited	3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
MX2018004256A (es)	2015-10-14	2018-05-16	Squibb Bristol Myers Co	Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
CA3001894A1 (en)	2015-10-14	2017-04-20	Bristol-Myers Squibb Company	Selective nr2b antagonists
ES2886840T3 (es)	2016-08-31	2021-12-21	Eisai R&D Man Co Ltd	Compuesto de pirazolo[1,5-a]pirimidina
WO2018098128A1 (en)	2016-11-22	2018-05-31	Rugen Holdings (Cayman) Limited	Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA03007621A (es) *	2001-02-23	2003-12-04	Merck & Co Inc	Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.

2004
- 2004-05-28 KR KR1020057023218A patent/KR20060017839A/ko not_active Ceased
- 2004-05-28 ES ES04753896T patent/ES2309540T3/es not_active Expired - Lifetime
- 2004-05-28 PT PT04753896T patent/PT1648882E/pt unknown
- 2004-05-28 BR BRPI0410837-0A patent/BRPI0410837A/pt not_active IP Right Cessation
- 2004-05-28 CN CNA2004800153228A patent/CN1798744A/zh active Pending
- 2004-05-28 MX MXPA05013151A patent/MXPA05013151A/es active IP Right Grant
- 2004-05-28 CA CA002527093A patent/CA2527093C/en not_active Expired - Lifetime
- 2004-05-28 DK DK04753896T patent/DK1648882T3/da active
- 2004-05-28 AU AU2004245522A patent/AU2004245522B2/en not_active Expired
- 2004-05-28 EP EP04753896A patent/EP1648882B1/de not_active Expired - Lifetime
- 2004-05-28 DE DE602004015610T patent/DE602004015610D1/de not_active Expired - Lifetime
- 2004-05-28 WO PCT/US2004/017175 patent/WO2004108705A1/en not_active Ceased
- 2004-05-28 RU RU2005137704/04A patent/RU2339630C2/ru not_active IP Right Cessation
- 2004-05-28 UA UAA200511411A patent/UA81319C2/uk unknown
- 2004-05-28 HR HR20080490T patent/HRP20080490T3/xx unknown
- 2004-05-28 PL PL04753896T patent/PL1648882T3/pl unknown
- 2004-05-28 AT AT04753896T patent/ATE403651T1/de not_active IP Right Cessation
- 2004-05-28 JP JP2006515051A patent/JP3927228B2/ja not_active Expired - Lifetime
- 2004-05-28 SI SI200430845T patent/SI1648882T1/sl unknown
- 2004-05-31 MY MYPI20042091A patent/MY138547A/en unknown
- 2004-05-31 AR ARP040101878A patent/AR044579A1/es unknown
- 2004-06-01 PE PE2004000552A patent/PE20050245A1/es not_active Application Discontinuation
- 2004-06-03 CL CL200401365A patent/CL2004001365A1/es unknown
- 2004-06-03 TW TW093115972A patent/TW200510378A/zh unknown
2005
- 2005-11-07 IS IS8117A patent/IS8117A/is unknown
- 2005-11-07 ZA ZA200509000A patent/ZA200509000B/en unknown
- 2005-11-28 MA MA28626A patent/MA27781A1/fr unknown
- 2005-11-29 EC EC2005006192A patent/ECSP056192A/es unknown
- 2005-11-30 CO CO05121658A patent/CO5700762A2/es not_active Application Discontinuation
2006
- 2006-01-03 NO NO20060020A patent/NO20060020L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MA27781A1 (fr)	2006-02-01
MXPA05013151A (es)	2006-03-17
RU2005137704A (ru)	2006-05-27
UA81319C2 (en)	2007-12-25
SI1648882T1 (sl)	2009-02-28
CA2527093A1 (en)	2004-12-16
EP1648882A1 (de)	2006-04-26
DK1648882T3 (da)	2008-11-24
PL1648882T3 (pl)	2008-12-31
TW200510378A (en)	2005-03-16
WO2004108705A1 (en)	2004-12-16
PE20050245A1 (es)	2005-04-13
JP2006526650A (ja)	2006-11-24
CL2004001365A1 (es)	2005-05-06
CO5700762A2 (es)	2006-11-30
KR20060017839A (ko)	2006-02-27
DE602004015610D1 (de)	2008-09-18
IS8117A (is)	2005-11-07
AU2004245522B2 (en)	2009-10-29
BRPI0410837A (pt)	2006-06-27
CN1798744A (zh)	2006-07-05
RU2339630C2 (ru)	2008-11-27
CA2527093C (en)	2009-10-20
JP3927228B2 (ja)	2007-06-06
ECSP056192A (es)	2006-04-19
EP1648882B1 (de)	2008-08-06
NO20060020L (no)	2006-03-03
HRP20080490T3 (en)	2008-11-30
AU2004245522A1 (en)	2004-12-16
ZA200509000B (en)	2006-12-27
MY138547A (en)	2009-06-30
AR044579A1 (es)	2005-09-21
ES2309540T3 (es)	2008-12-16
PT1648882E (pt)	2008-10-20

Legal Events

Date

Code

Title

Description

2009-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1648882

Country of ref document: EP

2010-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE602004004278D1 (de)	2007-02-22	4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
DE50304983D1 (de)	2006-10-19	Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de)	2010-02-04	Pyrimidopyrimidone als kinaseinhibitoren
DE602004015724D1 (de)	2008-09-25	Diazepinoindolderivate als kinaseinhibitoren
DE60331751D1 (de)	2010-04-29	N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DE602004024420D1 (de)	2010-01-14	Chinazolinderivate als antitumormittel
ATE392897T1 (de)	2008-05-15	Chinolinderivate als npy antagonisten
NO20054198D0 (no)	2005-09-09	Sentrifugalkompressorenhet
DE602004025473D1 (de)	2010-03-25	Mehrkomponentiges spinnvlies
DK1648882T3 (da)	2008-11-24	3-fluor-piperidiner som NMDA/NR2B-antagonister
DE60335075D1 (de)	2011-01-05	Flüssigkeitszerstäuber
DE60316411D1 (de)	2007-10-31	Thiazolderivate als npy-rezeptorantagonisten
DE602004004295D1 (de)	2007-02-22	6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de)	2008-05-15	G-lactamderivate als prostaglandinagonisten
ATE462688T1 (de)	2010-04-15	Diarylsulfone als 5-ht2a-antagonisten
ATE418542T1 (de)	2009-01-15	Als ccr5-antagonisten verwendbare aryloxim- piperazine
FI20031302A0 (fi)	2003-09-11	Kärkiteline
DK1633719T3 (da)	2010-01-04	Substituerede spirobenzazepiner
FR2852101B1 (fr)	2006-11-24	Pese-personne
FI20031496A0 (fi)	2003-10-14	Hissijärjestely
ATA8202003A (de)	2004-12-15	Hochspannungsmast
DE502004004196D1 (de)	2007-08-09	Ultraschall-stehwellen-zerstäuberanordnung
DE502004006442D1 (de)	2008-04-17	Bauelement
DE10346324B4 (de)	2005-10-20	Bauelemente-Anordnung
FI5863U1 (fi)	2003-07-10	Teline